



January 5, 2024

Press Release

Company: Kringle Pharma, Inc.
Address: 207 Saito Bio-Incubator, 7-7-15 Saitoasagi,
Ibaraki, Osaka 567-0085, Japan
Representative: President and CEO Kiichi Adachi
(Code: 4884; the Growth Market of Tokyo
Stock Exchange)
Contact: CFO Koichi Murakami
Phone. +81-72-641-8739

Analyst Report Released by Shared Research Inc.

Kringle Pharma, Inc. today announced the update and release of an analyst report "Full Report for the Fiscal Year Ending September 30, 2023" from Shared Research Inc.

The analyst reports prepared by Shared Research Inc. are intended to make in-depth understanding of companies, to increase the efficiency of investors' corporate research, and to enable constructive dialogue between companies and shareholders. In addition, this report provides objective information analyzed from a third-party perspective. It is a free report for informational purposes only and does not provide investment opinions or advice.

We believe that the contents of this analyst report, which cover our business structure and growth strategies, will help investors further deepen their understanding of our company and use this information as a reference in making investment decisions.

- Report release date: January 5, 2024
- URL of the report: <https://sharedresearch.jp/en/companies/4884>

* This report is a translation of the original Japanese-language report released on December 18, 2023.